Literature DB >> 25712539

Recurrent genomic rearrangements in primary testicular lymphoma.

David D W Twa1,2, Anja Mottok1,2, Fong Chun Chan1,3, Susana Ben-Neriah1, Bruce W Woolcock1, King L Tan1, Andrew J Mungall1,4, Helen McDonald4, Yongjun Zhao4, Raymond S Lim1, Brad H Nelson5,6, Katy Milne5, Sohrab P Shah1,3, Ryan D Morin1,7, Marco A Marra1,4, David W Scott1, Randy D Gascoyne1,2, Christian Steidl1,2.   

Abstract

Primary testicular diffuse large B cell lymphoma (PTL) is an aggressive malignancy that occurs in the immune-privileged anatomical site of the testis. We have previously shown that structural genomic rearrangements involving the MHC class II transactivator CIITA and programmed death ligands (PDLs) 1 and 2 are frequent across multiple B cell lymphoma entities. Specifically in PTL, we found rearrangements in the PDL locus by fluorescence in situ hybridization (FISH). However, breakpoint anatomy and rearrangement partners were undetermined, while CIITA rearrangements had not been reported previously in PTL. Here, we performed bacterial artificial chromosome capture sequencing on three archival, formalin-fixed, paraffin-embedded tissue biopsies, interrogating 20 known rearrangement hotspots in B cell lymphomas. We report novel CIITA, FOXP1 and PDL rearrangements involving IGHG4, FLJ45248, RFX3, SMARCA2 and SNX29. Moreover, we present immunohistochemistry data supporting the association between PDL rearrangements and increased protein expression. Finally, using FISH, we show that CIITA (8/82; 10%) and FOXP1 (5/74; 7%) rearrangements are recurrent in PTL. In summary, we describe rearrangement frequencies and novel rearrangement partners of the CIITA, FOXP1 and PDL loci at base-pair resolution in a rare, aggressive lymphoma. Our data suggest immune-checkpoint inhibitor therapy as a promising intervention for PTL patients harbouring PDL rearrangements.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  CD274; CIITA; FOXP1; PDCD1LG2; capture sequencing; fluorescence in situ hybridization (FISH); genomic rearrangements; primary testicular lymphoma (PTL); programmed death ligands

Mesh:

Substances:

Year:  2015        PMID: 25712539     DOI: 10.1002/path.4522

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

1.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

Review 2.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Authors:  Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 3.  Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies.

Authors:  Kerry J Savage
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  The emerging role of immune checkpoint inhibition in malignant lymphoma.

Authors:  Ida Hude; Stephanie Sasse; Andreas Engert; Paul J Bröckelmann
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

5.  Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.

Authors:  Ji Yuan; George Wright; Andreas Rosenwald; Christian Steidl; Randy D Gascoyne; Joseph M Connors; Anja Mottok; Dennis D Weisenburger; Timothy C Greiner; Kai Fu; Lynette Smith; Lisa M Rimsza; Elaine S Jaffe; Elias Campo; Antonio Martinez; Jan Delabie; Rita M Braziel; James R Cook; German Ott; Julie M Vose; Louis M Staudt; Wing C Chan
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

Review 6.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

7.  Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Authors:  Aaron M Goodman; David Piccioni; Shumei Kato; Amélie Boichard; Huan-You Wang; Garrett Frampton; Scott M Lippman; Caitlin Connelly; David Fabrizio; Vincent Miller; Jason K Sicklick; Razelle Kurzrock
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

Review 8.  New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-06-17       Impact factor: 0.196

9.  FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

Authors:  P J Brown; K K Wong; S L Felce; L Lyne; H Spearman; E J Soilleux; L M Pedersen; M B Møller; T M Green; D M Gascoyne; A H Banham
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

Review 10.  Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Authors:  Marie de Charette; Roch Houot
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.